Stock listing
RAPP Stock Price, News, Filings & Events — Rapport Therapeutics, Inc.
Selected listing: RAPP · NASDAQ · USD · US
This page tracks Rapport Therapeutics, Inc.'s RAPP:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following RAPP:NASDAQ. RAPP:NASDAQ is the stock-level entry point for investors researching Rapport Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Rapport Therapeutics, Inc. (Ticker: RAPP) is a public company operating in the American market, with a market capitalization of approximately $2.04 billion. The company focuses on developing innovative therapeutic solutions. Investors can find more information about its operations and performance on its dedicated public company page.

- Ticker
- RAPP:NASDAQ
- Asset type
- Stock
- Market cap
- $2.09B
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
Rapport Therapeutics, Inc. RAPP:NASDAQ stock context
This page tracks Rapport Therapeutics, Inc.'s RAPP:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following RAPP:NASDAQ. RAPP:NASDAQ is the stock-level entry point for investors researching Rapport Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Rapport Therapeutics, Inc. (Ticker: RAPP) is a public company operating in the American market, with a market capitalization of approximately $2.04 billion. The company focuses on developing innovative therapeutic solutions. Investors can find more information about its operations and performance on its dedicated public company page.
Latest news from Rapport Therapeutics, Inc.
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
August 24, 2026
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
August 5, 2026
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
May 20, 2026
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
May 7, 2026
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at ...
April 21, 2026
Research Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for RAPP:NASDAQ.
Rapport Therapeutics, Inc. company profile
View the public company page for Rapport Therapeutics, Inc. on 6ix.
Rapport Therapeutics, Inc. news
Read company news and market updates connected to Rapport Therapeutics, Inc..
Rapport Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Rapport Therapeutics, Inc..